Prolonged Suppression of Human Immunodeficiency Virus Type 1 RNA during Dual Nucleoside Reverse‐Transcriptase–Inhibitor Therapy in Clinical Practice | Zendy

Craig Hoesley | Zendy; Michael S. Saag | Zendy; Ashlee Chatham | Zendy; J Michael Kilby | Zendy

Open Access

Prolonged Suppression of Human Immunodeficiency Virus Type 1 RNA during Dual Nucleoside Reverse‐Transcriptase–Inhibitor Therapy in Clinical Practice

Author(s) -

Craig Hoesley,

Michael S. Saag,

Ashlee Chatham,

J Michael Kilby

Publication year - 2000

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/318143

Subject(s) - nucleoside reverse transcriptase inhibitor , reverse transcriptase , medicine , virology , reverse transcriptase inhibitor , human immunodeficiency virus (hiv) , lentivirus , nucleoside , rna , virus , antiretroviral therapy , sida , viral disease , viral load , biology , genetics , gene

Because there is limited information about suppression of virus loads (determined by current "ultrasensitive" assays) in patients receiving nucleoside reverse-transcriptase inhibitors (NRTIs) alone, we reviewed our experience in clinical practice with patients who had virus loads of <25 copies/mL after >1 year of treatment with dual NRTIs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research